Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

tes from discovery into the clinic."

Principal investigator Osama Gaber, M.D., F.A.C.S. Director, Transplant Center of Excellence at The Methodist Hospital, Houston, Texas said, "Our clinical team is excited to participate in clinical trials that evaluate new therapies for renal transplant patients. Patients that develop DGF following renal transplantation have inferior kidney graft survival compared to those who do not. There is a real unmet medical need for a drug product to prevent DGF."

Daniel Zurr, Chief Executive Officer, commented, "We are very pleased to announce initiation of human dosing of the systemically administered QPI-1002 in our Phase I/II trial in kidney transplant patients. Furthermore, our siRNA drug candidate, PF-4523655, has been advanced into two Phase II clinical trials -- one for diabetic macular edema and the other for age related macular degeneration -- by our licensee, Pfizer. In addition, we recently announced that our QPI-1007 drug candidate, utilizing a novel siRNA structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. These significant developments confirm the robustness of Quark's clinical pipeline and the strength of its capabilities in the RNAi arena."

Delayed graft function (DGF) is one of the most common complications during the immediate postoperative period in renal transplantation and affects 25-40% of the deceased donor renal transplants in the United States. DGF in renal transplantation results most often from ischemia-reperfusion injury that occurs when the blood flow is re-established to the transplanted kidney initiating a chain of events that can lead to severe renal damage upon transplantation. Post-kidney transplant DGF is associated with longer hospital stays and higher rates of graft rejection, which in turn decreases the survival of the transplanted kidney (graft survival). Current
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... N.Y., Nov. 9 /PRNewswire/ -- On Sept. 11, 2001,...her rescue workers came together to save as many l...hter Brian McCauley was one of those 9/11 first re... ,, Only in his late 30s, McCauley was diagnose...d extensive chemotherapy treatments, leaving him c...
(Date:11/9/2009)... Nov. 9 Women,s sexual health comp...ame to Viveve as it prepares for a 2010 launch of ...s. ,, "Viveve is a name that we believe capture...al health," said Kerry Pope, Viveve,s president an...pose of helping women restore their sense of fulfi...
(Date:11/9/2009).... 9 Boston Scientific Co... of its COGNIS® cardiac resynchronization the...ntable cardioverter defibrillator (ICD) in Japan. ...try of Health, Labor and Welfare (MHLW) in August ... COGNIS and TELIGEN are the result of a multi-year...
Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4ULURU Inc Presents Results of First Randomized Clinical Trial for Altrazeal 28TM 29 at the Symposium on Advanced Wound Care 28SAWC 29 Fall Meeting i 57387 1ULURU Inc Presents Results of First Randomized Clinical Trial for Altrazeal 28TM 29 at the Symposium on Advanced Wound Care 28SAWC 29 Fall Meeting i 57387 2Exercise Benefits Even the Oldest Old 57383 1Exercise Benefits Even the Oldest Old 57383 2Pennsylvania Breast Cancer Coalition Hosts Annual Conference 57378 1Pennsylvania Breast Cancer Coalition Hosts Annual Conference 57378 2
...ne on Aug. 5 in Nature Journal, CLEVELAND, Aug. 7...the region within high density lipoprotein (HDL), ...become dysfunctional within the,artery wall, inhib...dup. The work of the researchers led by Stanley H...ve Cardiology and Rehabilitation at Cleveland Clin...
...uing Progress on Clinical and Preclinical Programs... (Amex: KAL; FWB: CA4), a developer of new drug tr...estinal diseases, is pleased to provide an,update ...ties for the,second quarter of 2007. "Callisto ha...preclinical programs in 2007," stated Gary S. Jaco...
Other Medicine Technology:Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 2Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 3Callisto Reports on Second-Quarter 2007 Milestones 2Callisto Reports on Second-Quarter 2007 Milestones 3Callisto Reports on Second-Quarter 2007 Milestones 4
(Date:11/9/2009)...tCall/ - Hard To Treat Diseases (HTDS.PK) www.htd...$41 billion international healthcare company, is a...r, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.,...begin a five-year, $1 billion China initiative wit... its investment in its China R&D facility, and...
(Date:11/9/2009)...late when it comes to preventing or improving a di...ke Off Pounds Sensibly), the nonprofit weight-loss...(Vocus) November 9, 2009 -- Tomorrow may be too la...etes condition, according to TOPS Club, Inc. (Take...upport organization., , ,Diabetes is a disease in ...
(Date:11/9/2009)... positive influence of sports participation on bon...Vocus) November 9, 2009 -- As people age fractures...ch has highlighted the importance of exercise and ...However, a new study published in the November/Dec... Approach reveals that there may be significant g...
(Date:11/9/2009).../ -- Actress Mariska Hargitay and the Joyful Hea...to raise awareness about the need for domestic vio...ilding healing and wellness kits for women in cris... to each of the estimated 600 women currently bein...iolence shelters. ,, "Our goal is to shine a li...
(Date:11/9/2009)...assador ,, WHITE PLAINS, N.Y., Nov. 9 /PRNews..., was born so early and with so many underdevelope...ld survive -- or if he would ever walk, talk, see ...Dimes 2010 National Ambassador. ,, Joshua,s mo...motherhood and I was completely devastated. My hus...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3
...to be a common condition among the senior lot in A...heir recovery process from an illness or accident...Sydneys Prince of Wales Hospital showed that almos...of stay in the hospital. Associate Profes...
...rough suppressing communication between the cells ...epsy and schizophrenia. Researchers at th...a protein that could do the trick. The SUMO protei...kling diseases such as epilepsy and schizophrenia,...
...utated with no recourse, injected stem cells could...g. Thus stem cells offer immense hope to scientis... patient. Now, scientists have explored th...mbryos, called hemangioblast cells are capable of ...
...the lesser of two evils or the better of two goods...d by just one name , is a severely disabled nine -...sability, mental disability as well renders her mi... whom they refer to as the pillow angel, on an onl...
...es not do any good to the human body, it is known.... lot may have higher blood pressure and heart rat...s hormones that strain the heart, more depression ...ally let go of things, shows a new study by psycho...
...nd psychology research both indicate that paying c...cing something else. However, a new study... that attention does not have a fixed capacity - a...psychology and psychiatry professor Richard Davids...
Other Medicine News:Health News:British Scientists Discover New Protein to Treat Epilepsy and Schizophrenia 2Health News:Human Rights Activists Sleepless In Seattle 2Health News:Brooding Could Kill, Warn Psychologists 2Health News:Meditation May Fine-Tune Control Over Attention 2
Calcitonin Assay Immunoradiometric (IRMA) Assay
...licular C-cells of the thyroid gland and is packag...itonin is to lower plasma calcium concentrations, ...creased mobilization of calcium from bone [1]. Thi...with high levels of bone remodeling (e.g. in Paget...
Calcitonin RIA Kit
...n Frequency Doubling Technology. It represents a s... combining early glaucoma detection capabilities, ...management tools., ,Like the Humphrey FDT Peri... screener with 35 second supra-threshold testing. ...
Medicine Products: